In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Latest From Dyax Corp

J&J Gets Into The Anti-TSLP Game With Proteologix Buyout

The privately held biotech will bring J&J a pair of bispecific antibodies expected to target multiple pathologic pathways in atopic dermatitis and asthma.

M & A Business Strategies

AstraZeneca Pays $2bn To Keep Up With The Joneses

Bristol Myers Squibb and Lilly have recently done billion-dollar radiopharmaceuticals deals, and now the UK group wants a piece of the market. But can it make its Fusion fusion work?

Deals Companies

Latigo Raises $135m To Channel Vertex

The start-up is aiming to develop a NaV1.8 inhibitor for pain, but previous efforts here have met with more failure than success.

Commercial Companies

What’s New, And What’s Coming, In Radiopharmaceuticals

Novartis is the leader when it comes to targeted cancer therapies incorporating radioisotopes. But plenty of companies are trying to break in to this market.

Clinical Trials Commercial
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Drug Discovery Technologies
      • Molecular Diversity